GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (NAS:ACET) » Definitions » 3-Year Revenue Growth Rate

Adicet Bio (Adicet Bio) 3-Year Revenue Growth Rate : 0.00% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio 3-Year Revenue Growth Rate?

Adicet Bio's Revenue per Share for the three months ended in Dec. 2023 was $0.00.

During the past 12 months, Adicet Bio's average Revenue per Share Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 6 years, the highest 3-Year average Revenue per Share Growth Rate of Adicet Bio was 128.40% per year. The lowest was -9.10% per year. And the median was 59.65% per year.


Competitive Comparison of Adicet Bio's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Adicet Bio's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adicet Bio's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Adicet Bio's 3-Year Revenue Growth Rate falls into.



Adicet Bio 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Adicet Bio  (NAS:ACET) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Adicet Bio 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Adicet Bio's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Adicet Bio (Adicet Bio) Business Description

Traded in Other Exchanges
Address
200 Clarendon Street, Floor 6, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.
Executives
Chen Schor director, officer: See Remarks PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Katie Peng director C/O ADICET BIO, INC., 200 BERKELEY STREET, 19TH FLOOR, BOSTON MA 02116
Steve Dubin director
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Don Healey officer: Chief Technology Officer 2635 TECHNOLOGY FOREST BOULEVARD, THE WOODLANDS TX 77381
Blake Aftab officer: Chief Scientific Officer C/O ADICET BIO, INC., 200 CLARENDON STREET, FLOOR 6, BOSTON MA 02116
Francesco Galimi officer: Chief Medical Officer 12930 VIA ESPERIA, DEL MAR CA 92014
Aya Jakobovits director 3135 HUTTON DRIVE, BEVERLY HILLS CA 90210
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Andrew Sinclair director C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Michael Kauffman director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Bastiano Sanna director C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210
Orbimed Capital Gp V Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carrie Krehlik officer: Chief Human Resources Officer 6015 COLTON BLVD, OAKLAND CA 94611